ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2214

Similar Levels of Disease Activity in Patients with Oligoarticular Vs. Polyarticular Peripheral Spondyloarthritis

Filip Van den Bosch1, Philip J. Mease2, Désirée van der Heijde3, Martin Rudwaleit4, Katie Obermeyer5 and Aileen L. Pangan5, 1Ghent University Hospital, Ghent, Belgium, 2Rheumatology Research, Swedish Medical Center, Seattle, WA, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Endokrinologikum Berlin, Berlin, Germany, 5Abbott Laboratories, Abbott Park, IL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adalimumab and spondylarthropathy

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: The ASAS criteria for peripheral spondyloarthritis (SpA) allow for classification of patients with SpA who present with peripheral arthritis, enthesitis and/or dactylitis.1 ABILITY-2, a placebo-controlled trial of adalimumab (ADA) for the treatment of peripheral SpA in patients not previously diagnosed with psoriasis or psoriatic arthritis (PsA), is the first pivotal study to use the ASAS criteria to classify patients for study entry. This analysis characterizes ABILITY-2 patients based on gender and the pattern of joint involvement – oligoarticular vs. polyarticular.

Methods: ABILITY-2 is an ongoing, randomized, controlled multicenter phase 3 study. Eligible patients were age ≥18 yrs, fulfilled ASAS peripheral SpA criteria, did not have a diagnosis of psoriasis, PsA, or ankylosing spondylitis, and had inadequate response or intolerance to NSAIDs. Required baseline disease activity at study entry included patient global assessment of disease activity (PGA) and of pain (PGA-pain) ≥40mm (0–100 mm VAS), ≥2 SJC and TJC, ≥2 digits with dactylitis or enthesitis accompanied by at least 1 joint with active arthritis, or ≥2 sites with enthesitis judged to be severe by the investigator.  Subgroup analyses of baseline demographics and disease activity were conducted by gender and by pattern of joint involvement (oligoarticular 2–4 vs. polyarticular >4 joints which are either tender and/or swollen).

Results: Of the 165 patients randomized, 90 (54.5%) were female and 125 (75.8%) had polyarticular disease. Females were slightly older and had a lower proportion with HLA-B27 positivity, but overall, had similar disease activity parameters as males (table). Predominantly lower limb involvement was observed at baseline in 57% of males, 50% of females, 59% of patients with oligoarticular disease, and 51% of patients with polyarticular disease. More patients with polyarthritis were HLA-B27+ compared to those with oligoarthritis (table). Although fewer polyarticular patients had an abnormal hs-CRP at baseline, the mean hs-CRP and the proportion of patients with accompanying enthesitis and dactylitis were greater in those with polyarticular disease. Otherwise, both patient and physician global assessments, BASDAI, HAQ-S and the physical component score of the SF-36v2 were similar between these 2 subgroups.

 Conclusion: In non-PsA peripheral SpA patients with inadequate response or intolerance to NSAIDs, similar levels of disease activity as measured by patient and physician global assessments were observed regardless of extent of joint involvement. Likewise, functional impairment was also comparable between patients with oligo- and polyarticular joint disease.

 

Table. Baseline demographics and disease characteristics in subgroups of peripheral SpA patients based on gender and pattern of joint involvement

Randomized Patients

N=165

Gender

Pattern of Joint  Involvement

Male

n = 75

Female

n = 90

Oligoarticular

n = 34

Polyarticular

n = 125

Demographics

Age, years

38.5

42.3

39.6

41.2

Female, %

–

–

55.9

55.2

SpA symptom durationa, years

6.62

7.67

6.65

7.45

HLA-B27+, %

65.3

58.4

52.9

62.1

Disease Activity

hs-CRP, mg/L

11.2

9.4

8.3

11.0

hs-CRP abnormal, %

46.7

41.1

52.9

42.4

TJC, 0–78

10.77

15.38

3.00

16.69

SJC, 0–76

6.21

7.11

2.12

8.24

MASES, 0–13

2.51

4.07

1.44

3.89

MASES >0, %

73.3

75.6

52.9

80.0

Leeds enthesitis index, 0–6

1.29

1.59

0.56

1.73

Leeds >0, %

65.3

60.0

44.1

68.0

SPARCC enthesitis index, 0–16

3.53

4.28

1.91

4.54

SPARCC >0, %

81.3

75.6

64.7

81.6

Dactylitis count

0.41

0.57

0.12

0.63

Dactylitis >0, %

20.0

24.7

8.8

27.4

PGA, 0–100 mm

63.71

67.59

63.97

66.50

PGA-pain, 0–100 mm

62.45

67.01

62.47

65.70

PhGA, 0–100 mm

59.29

58.18

56.12

59.72

BASDAI, 0–10

5.21

5.97

5.37

5.72

SF-36v2 PCS

35.65

33.58

36.77

33.88

HAQ-S

0.83

1.11

0.88

1.02

Values are the mean unless otherwise indicated. aN=73, 88, 34, 121, respectively. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; HAQ-S, Health Assessment Questionnaire modified for Spondyloarthropathies; hs-CRP, high-sensitivity C-reactive protein; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; PGA, Patient’s Global Assessment of disease activity; PGA-pain, Patient’s Global Assessment of pain; PhGA, Physician’s Global Assessment; SF-36v2 PCS, Short Form-36 Health Status Survey version 2 physical component summary; SJC, swollen joint count; SpA, spondyloarthritis; SPARCC, Spondyloarthritis Research Consortium of Canada; TJC, tender joint count

References

1. Ann Rheum Dis 2011;70:25–31.


Disclosure:

F. Van den Bosch,

Abbott, Merck, Pfizer, and UCB,

5,

Abbott, Merck, Pfizer, and UCB,

8;

P. J. Mease,

Abbott, Amgen, BiogenIdec, Bristol Myers, Celgene, Genentech, Janssen, Lilly,Merck, Novartis, Pfizer, and UCB,

2,

Abbott, Amgen, BiogenIdec, Bristol Myers, Celgene, Genentech, Janssen, Lilly,Merck, Novartis, Pfizer, and UCB,

5;

D. van der Heijde,

Abbott Laboratories; Amgen; AstraZeneca; BMS; Centocor: Chugai; Eli-Lilly; GSK; Merck; Novartis; Pfizer; Roche; Sanofi-Aventis; Schering-Plough; UCB; Wyeth,

5,

Abbott Laboratories; Amgen; AstraZeneca; BMS; Centocor: Chugai; Eli-Lilly; GSK; Merck; Novartis; Pfizer; Roche; Sanofi-Aventis; Schering-Plough; UCB; Wyeth,

2,

Imaging Rheumatology,

4;

M. Rudwaleit,

Abbott, BMS, MSD, Pfizer, Roche, and UCB,

5;

K. Obermeyer,

Abbott Laboratories,

1,

Abbott Laboratories,

3;

A. L. Pangan,

Abbott Laboratories,

3,

Abbott Laboratories,

1.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/similar-levels-of-disease-activity-in-patients-with-oligoarticular-vs-polyarticular-peripheral-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology